Our results also suggest that pretreatment of EZH2GOF DLBCL cells with HDAC1,2-selective inhibitor sensitizes cells to doxorubicin which results in increased DNA damage response and increased number of γH2AX-containing double-strand breaks. The gene discussed is HDAC1; the disease is diffuse large B-cell lymphoma.